$ONCT
Oncternal Therapeutics Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020050576 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q3
Revenue $590.0K $623.0K $544.0K
YoY Change 8.46% -7.01% 65.35%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.930M $2.340M $2.390M
YoY Change -19.25% 44.44% 10.65%
% of Gross Profit
Research & Development $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.980M $6.158M $5.493M
YoY Change -9.34% -72.38% 142.73%
Operating Profit -$4.395M -$5.535M -$4.949M
YoY Change -11.19% -74.4% 155.89%
Interest Expense $0.00 $0.00 $60.00K
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $57.00K
YoY Change -100.0% -100.0% 58.33%
Pretax Income -$4.400M -$5.540M -$4.890M
YoY Change -10.02% -75.75% -48.14%
Income Tax
% Of Pretax Income
Net Earnings -$4.395M -$5.535M -$4.892M
YoY Change -10.16% -75.77% 157.74%
Net Earnings / Revenue -744.92% -888.44% -899.26%
Basic Earnings Per Share
Diluted Earnings Per Share -$218.6K -$341.1K -$318.8K
COMMON SHARES
Basic Shares Outstanding 15.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.30M $16.60M $23.10M
YoY Change -7.79% -41.75% -39.37%
Cash & Equivalents $21.30M $16.60M $23.10M
Short-Term Investments
Other Short-Term Assets $1.400M $1.400M $1.000M
YoY Change 40.0% 0.0% -52.38%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.70M $18.00M $24.10M
YoY Change -5.81% -39.74% -39.9%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $100.0K $200.0K
YoY Change -50.0% -66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $800.0K $768.0K
YoY Change 4.17% 4.3%
Total Long-Term Assets $900.0K $900.0K $949.0K
YoY Change -5.16% -12.79% 374.5%
TOTAL ASSETS
Total Short-Term Assets $22.70M $18.00M $24.10M
Total Long-Term Assets $900.0K $900.0K $949.0K
Total Assets $23.60M $18.90M $25.05M
YoY Change -5.78% -38.84% -37.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.000M $1.500M $1.231M
YoY Change -18.77% -45.75% -60.29%
Accrued Expenses $3.273M $3.607M $2.435M
YoY Change 34.41% 41.45% -60.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.600M $9.000M $6.770M
YoY Change 12.26% 14.78% -27.2%
LONG-TERM LIABILITIES
Long-Term Debt $300.0K $300.0K $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $300.0K $300.0K $100.0K
YoY Change 200.0% 200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.600M $9.000M $6.770M
Total Long-Term Liabilities $300.0K $300.0K $100.0K
Total Liabilities $7.900M $9.300M $6.900M
YoY Change 14.49% 16.25% -25.81%
SHAREHOLDERS EQUITY
Retained Earnings -$80.20M -$75.80M -$61.42M
YoY Change 30.58% 34.1%
Common Stock $15.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.70M $9.598M $18.15M
YoY Change
Total Liabilities & Shareholders Equity $23.60M $18.90M $25.05M
YoY Change -5.78% -38.84% -37.84%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q3
OPERATING ACTIVITIES
Net Income -$4.395M -$5.535M -$4.892M
YoY Change -10.16% -75.77% 157.74%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.320M -$4.220M -$3.830M
YoY Change 38.9% -32.37% -50.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$1.600M
YoY Change -100.0% -100.0% -111.25%
Cash From Investing Activities $0.00 $0.00 -$1.600M
YoY Change -100.0% -100.0% -111.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.970M 4.820M 20.00K
YoY Change 49750.0% -75.0%
NET CHANGE
Cash From Operating Activities -5.320M -4.220M -3.830M
Cash From Investing Activities 0.000 0.000 -1.600M
Cash From Financing Activities 9.970M 4.820M 20.00K
Net Change In Cash 4.650M 600.0K -5.410M
YoY Change -185.95% -94.82% -182.22%
FREE CASH FLOW
Cash From Operating Activities -$5.320M -$4.220M -$3.830M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1933000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
4980000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4395000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1268000
us-gaap Share Based Compensation
ShareBasedCompensation
192000
onct Noncash Compensation Expense
NoncashCompensationExpense
56000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1268000
onct Noncash Lease Expense
NoncashLeaseExpense
111000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
711000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
268000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
106000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4402000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
958000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1555000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
57000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
57000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4395000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-4892000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20126
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15340
us-gaap Profit Loss
ProfitLoss
-14668000
us-gaap Profit Loss
ProfitLoss
-30032000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
18088000
us-gaap Share Based Compensation
ShareBasedCompensation
1149000
onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-111000
onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-56000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-418000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13584000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
18292000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
2155000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16137000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
301000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1000
onct Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
729000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
15700000
onct Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
46588000
onct Reclassification Of Preferred Stock Warrants Liability To Additional Paid In Capital
ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital
1942000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
5176000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
8000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9598000
CY2020Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1165000
CY2020Q3 onct Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
10087000
CY2020Q3 onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
3000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
407000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4395000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
15700000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
22936000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2019Q3 onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
1000
CY2019Q3 onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
3000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-4892000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
14312000
onct Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
14479000
onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
9000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1149000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
415000
us-gaap Net Income Loss
NetIncomeLoss
-14668000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-29631000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
1000
onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
27000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
29049000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
46588000
onct Adjustments To Additional Paid In Capital Reclassification Of Convertible Preferred Stock Warrant
AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant
1942000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
192000
us-gaap Net Income Loss
NetIncomeLoss
-30032000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
18150000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80200000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company’s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company’s preferred stock, preferred stock warrant liability and stock-based awards, and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p>
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
27000
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
3600000
CY2020Q3 us-gaap Deferred Revenue
DeferredRevenue
3200000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
23000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5882
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2809
CY2020Q3 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1705000
CY2019Q4 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1206000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
203000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
424000
CY2020Q3 onct Accrued Unvested Share Liability
AccruedUnvestedShareLiability
14000
CY2019Q4 onct Accrued Unvested Share Liability
AccruedUnvestedShareLiability
24000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1262000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
825000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
89000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3273000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2731000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
41000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
41000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
82000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
79000
us-gaap General Insurance Expense
GeneralInsuranceExpense
1400000
us-gaap General Insurance Expense
GeneralInsuranceExpense
1200000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
200000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
18100000
CY2020Q3 onct Liability For Unvested Cash Settled Share Based Payment Transactions
LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
14000
CY2019Q4 onct Liability For Unvested Cash Settled Share Based Payment Transactions
LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
24000
CY2020Q3 onct Common Stock Warrants Reserved For Future Issuance
CommonStockWarrantsReservedForFutureIssuance
3521000
CY2020Q3 onct Common Stock Options Issued And Outstanding For Future Issuance
CommonStockOptionsIssuedAndOutstandingForFutureIssuance
2341000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
35000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
15000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
20000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.007
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.986
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.769
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.922
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.769
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
407000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
90000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1149000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3900000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y9M18D
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6705000

Files In Submission

Name View Source Status
0001564590-20-050576-index-headers.html Edgar Link pending
0001564590-20-050576-index.html Edgar Link pending
0001564590-20-050576.txt Edgar Link pending
0001564590-20-050576-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
onct-10q_20200930.htm Edgar Link pending
onct-10q_20200930_htm.xml Edgar Link completed
onct-20200930.xsd Edgar Link pending
onct-20200930_cal.xml Edgar Link unprocessable
onct-20200930_def.xml Edgar Link unprocessable
onct-20200930_lab.xml Edgar Link unprocessable
onct-20200930_pre.xml Edgar Link unprocessable
onct-ex311_8.htm Edgar Link pending
onct-ex312_9.htm Edgar Link pending
onct-ex321_7.htm Edgar Link pending
onct-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending